Avid Bioservices Inc (CDMO)

[sulaco]

IMMUNO-ONCOLOGY: Bavi front and center

Yesterday? Dark clouds on the Board. Today? SUNRISE.


TO WIT:


We believe the encouraging preclinical combination treatment data are due in part to the ability of bavituximab to facilitate an increase in tumor-specific cytotoxic T-cell activity, a function that appears to expand and broaden the potential of immunotherapeutic agents including anti-CTLA-4 and anti-PD-1 which prime and sustain T-cell mediated killing of tumor cells in our pre-clinical models. We are continuing to explore these and other immunotherapy combinations and look forward to reporting additional results as they become available."

Read more: http://www.nasdaq.com/press-release/data-presentation-at-society-for-immunotherapy-of-cancer-annual-meeting-supports-potential-of-peregrine-pharmaceuticals-novel-immunotherapy-bavituximab-in-combination-with-anti-ctla-4-antibodies-20131108-00390#ixzz2k51QHJlx